Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.

ABSTRACT:

Importance

Treatment options for psoriasis (PsO) and psoriatic arthritis (PsA) have evolved significantly throughout the era of biologics. Clinical trials are inadequate to assess the relative long-term efficacy of biologics and are often insufficient regarding safety.

Objectives

To assess the long-term persistence of different biologic classes to treat PsO and PsA.

Design, setting, and participants

This nationwide cohort study involved the administrative health care database of the French health insurance scheme linked to the hospital discharge database. All adults with PsO and PsA who were new users of biologics (not in the year before the index date) from January 1, 2015, to May 31, 2019, were included and followed up through December 31, 2019. Patients hospitalize

SUBMITTER: Pina Vegas L 

PROVIDER: S-EPMC8943623 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature